Recent Price Movement and Market Context
On 9 Mar 2026, Windlas Biotech opened with a gap down of -2.05%, continuing a three-day losing streak that has seen the stock fall by -3.98% cumulatively. The day’s trading was marked by high volatility, with an intraday price range between Rs.708.9 and Rs.771.95, representing a 6.81% weighted average volatility. The stock closed at its lowest point of the day, Rs.708.9, down -2.01% from the previous close, underperforming the Pharmaceuticals & Biotechnology sector by -1.47%.
Windlas Biotech’s share price is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This contrasts with the broader market, where the Sensex opened sharply lower at 77,056.75, down -2.36%, and was trading at 77,134.00 (-2.26%) during the session. The Sensex itself has been on a three-week consecutive decline, losing -6.86% over this period.
Long-Term Performance and Valuation Metrics
Over the past year, Windlas Biotech’s stock has delivered a negative return of -20.82%, significantly lagging the Sensex’s positive 3.77% gain and the BSE500’s 6.76% return. The stock’s 52-week high was Rs.1,137.6, highlighting the extent of the recent decline. Despite this, the company maintains a relatively attractive valuation with a Price to Book Value ratio of 2.9 and a Return on Equity (ROE) of 12.6%, indicating some underlying asset efficiency and profitability.
However, the company’s Mojo Score stands at 37.0 with a Mojo Grade of Sell, downgraded from Hold on 4 Feb 2026. The Market Cap Grade is rated at 3, reflecting modest market capitalisation relative to peers. The PEG ratio of 3.2 suggests that the stock’s price may be high relative to its earnings growth, which has been moderate at 8.2% over the past year.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Financial Results and Profitability Trends
Windlas Biotech’s recent quarterly results have shown signs of stagnation. The Profit After Tax (PAT) for the latest quarter stood at Rs.15.00 crores, reflecting a decline of -10.9% compared to the previous four-quarter average. The Profit Before Depreciation, Interest and Taxes (PBDIT) was reported at Rs.24.38 crores, marking the lowest quarterly figure in recent periods. Cash and cash equivalents at the half-year mark were also at a low of Rs.15.03 crores, indicating limited liquidity buffers.
Despite these subdued earnings, the company’s debt to equity ratio remains low, averaging zero, which suggests a conservative capital structure with minimal leverage. This financial prudence may provide some stability amid earnings pressure.
Shareholding and Market Position
The majority shareholding remains with the promoters, maintaining control over strategic decisions. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance amid broader market volatility and sector-specific challenges.
Windlas Biotech Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Concerns
The stock’s decline to Rs.708.9 represents a significant technical and psychological level, reflecting investor caution amid a combination of factors. These include the company’s flat to declining quarterly earnings, low cash reserves, and underperformance relative to the broader market and sector indices. The downgrade in Mojo Grade from Hold to Sell further underscores the challenges faced by Windlas Biotech in sustaining growth momentum.
Additionally, the stock’s trading below all major moving averages signals persistent downward pressure, while the broader market environment remains weak, with the Sensex also experiencing a notable correction over recent weeks.
Valuation and Comparative Positioning
Despite the recent price weakness, Windlas Biotech’s valuation metrics such as ROE and Price to Book Value suggest that the stock is trading at a fair value relative to its historical averages and peer group. The company’s low leverage and promoter backing provide some structural stability. However, the modest growth in operating profit over the last five years at an annual rate of 18.82% has not translated into commensurate stock price appreciation, as reflected in the current market capitalisation and Mojo Score.
Investors monitoring the stock will note the contrast between the company’s fundamental attributes and its recent price performance, which has been influenced by both internal financial results and external market conditions.
Market and Sector Dynamics
The Pharmaceuticals & Biotechnology sector has faced mixed fortunes, with some stocks outperforming while others, including Windlas Biotech, have struggled to maintain upward momentum. The sector’s performance today was weaker than the broader market, with Windlas Biotech underperforming its peers by 1.47%. The India VIX index hitting a new 52-week high signals elevated market volatility, which may be contributing to the cautious sentiment surrounding stocks in this space.
Conclusion
Windlas Biotech Ltd’s fall to a 52-week low of Rs.708.9 on 9 Mar 2026 highlights a period of subdued performance amid challenging market conditions and company-specific financial trends. The stock’s underperformance relative to the Sensex and sector benchmarks, combined with recent downgrades and weak quarterly earnings, has weighed on investor sentiment. While valuation metrics indicate a fair price relative to fundamentals, the stock remains under pressure as it trades below all key moving averages and continues its downward trajectory.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
